期刊文献+

753例重型肝炎病原学及预后相关因素分析 被引量:10

Analysis of Etiologtic and Prognostic Factors in 753 Cases of Severe Hepatitis
下载PDF
导出
摘要 目的了解各型重型肝炎患者的病原学及影响其预后的危险因素。方法采用回顾性调查分析方法,对753例重型肝炎患者的病原学、年龄、各项生化、PTA和病毒指标等预后相关因素应用SPSS13.0软件包进行统计分析。结果①各型重型肝炎的预后不同,各组间有显著性差异;②乙型肝炎是慢性重型肝炎的最主要病因;③年龄、凝血酶原活动度(PTA)、总胆红素(TB)、总胆固醇(CHO)是影响预后的重要的实验室指标;④乙肝HBeAg阴性且HBV-DNA高表达者,病死率增高,有显著差异。结论重型肝炎以慢性乙型重型肝炎为主,年龄、凝血酶原活动度(PTA)、总胆红素(TB)、总胆固醇(CHO)以及乙肝前C区基因变异与慢性重型肝炎预后相关,可作为评价预后的重要指标。 Objective To further understand severe hepatitis through analyzing the etiology and risk factors affecting the prognosis of severe hepatitis.Methods SPSS 13.0 software was used to analyze the etiology,age,biochemistry,PTA and virus examination results et al affecting the prognosis of 753 cases with severe hepatitis treated in the Sixth People′s Hospital of Hangzhou from 2005 to 2008.Results ①There were significant differences in the prognosis between various types of severe hepatitis.The prognosis of acute liver failure was worst.②Hepatitis B was the most dominating etiology.③Age,prothrombin activity(PTA),total bilirubin(TBIL),cholesterol(CHO)were important laboratory factors affecting the prognosis of severe hepatitis.④The ratio of patients who had a serum HBV DNA level more than 5 log copies/mL in HBeAg-negative patients was significantly.Conclusion Severe hepatitis was miainly chronic severe hepatitis B.Age,prothrombin activity(PTA),total bilirubin(TB),total cholesterol(CHO),as well as hepatitis B pre-C gene mutation had association with prognosis of chronic severe hepatitis B,and can be used as an important prognostic indicator.
出处 《医学研究杂志》 2011年第2期96-98,共3页 Journal of Medical Research
关键词 重型肝炎 年龄 凝血酶原活动度 总胆固醇 乙肝前c区基因变异 Severe hepatitis Age Prothrombin activity Cholesterol Pre-c gene mutation
  • 相关文献

参考文献6

二级参考文献16

  • 1余桂芳,梁建新,曾文铤,朱科伦,马佩球.68例慢性重型乙型肝炎患者预后相关因素分析[J].广东医学,2006,27(3):386-388. 被引量:5
  • 2杜永国,何晶.重症肝炎患者相关指标检测的临床意义[J].中国热带医学,2006,6(8):1429-1429. 被引量:1
  • 3骆抗先.乙型肝炎基础与临床[M].北京:人民卫生出版社,1997.25.
  • 4Plevris JN, Schina M, Hayes PC. The management of acute liver failure[J]. Aliment Pharmacol Ther, 1998, 12(5): 405-418.
  • 5R akela J, Lange SM, Ludwig J, et al. Fulminant hepatitis: Mayo clinic experience with 34 cases [J]. Mayo Clin Proc, 1985,60(5):289-292.
  • 6Bowen DG, Shackel NA, Mccaughan GW. East meets West: acute liver failure in the global village[J]. J Gastroenterol Hepatol , 2000, 15(5):467-469.
  • 7O'Grady JG. Fulminant hepatitis in patients with chronic liver disease[J]. J Viral Hepat, 2000,7(Suppl 1):9-10.
  • 8Acharya SK, Panda SK, Saxena A, et al. Acute hepatic failure in India : a perspective from the East[J]. J Gastroenterol Hepatol, 2000, 15(5):473-479.
  • 9Ostapowicz G, Fontana RJ .Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States[J]. Ann Intern Med, 2002,137 (12):947-954.
  • 10Hoofnagle JH, Carithers Jr RL,Shapiro C, et al. Fulminant hepatic failure: summary of a workshop[J]. Hepatology, 1995, 21(1):240-252.

共引文献14063

同被引文献118

引证文献10

二级引证文献87

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部